Health Officials Monitor Arsenic Exposure Risks in Chiang Rai Waterways

  A recent study suggests that limiting daily meals to an eight- to nine-hour eating window may help support brain health, particularly in older women. The findings were presented at NUTRITION 2026, the annual meeting of the American Society for Nutrition, and are currently considered preliminary because the research has not yet been peer-reviewed. Scientists from Rutgers University found that women aged 50 to 79 who followed time-restricted eating while maintaining a calorie deficit performed better on certain cognitive tests than those who spread their meals over a typical 12-hour period. The six-month study included 47 overweight or obese women, all of whom reduced their daily calorie intake by about 500 calories. Of the participants, 26 consumed all of their meals within an average 8.2-hour window, while the remaining women ate over an average 12.3-hour period. Both groups lost nearly 15 pounds on average by the end of the study. However, the women who followed the shorter eating window performed better in spatial planning and problem-solving tasks. They also made fewer errors on learning and memory tests, although those improvements were not statistically significant. Researchers found no noticeable differences in reaction time or multitasking abilities. Lead researcher Dr. Sue Shapses, a professor at Rutgers University and Rutgers Robert Wood Johnson Medical School, said the findings suggest that meal timing may provide additional cognitive benefits beyond weight loss alone. She explained that finishing meals about four hours before bedtime and limiting eating to an eight- or nine-hour daily window may help reduce age-related cognitive decline. Researchers believe these benefits could be linked to the body’s circadian rhythm, metabolism, inflammation, and nutrient-sensing pathways, although more research is needed to confirm these effects. Experts cautioned that the findings should be interpreted carefully because the study involved a relatively small number of participants and has not yet undergone peer review. The researchers emphasized that larger and longer-term studies are needed to determine whether time-restricted eating can significantly improve long-term brain health and cognitive function. Until further evidence becomes available, the results provide encouraging but preliminary insights into how meal timing may influence healthy brain aging.

  Medical researchers have suggested that lithium, a widely available and inexpensive medication commonly prescribed to treat bipolar disorder and major depressive disorder, may also hold promise as a potential treatment for Alzheimer’s disease. Although the findings are encouraging, scientists stress that much more research is required before lithium can be recommended as a treatment for patients with Alzheimer’s. According to previous studies researchers found that people diagnosed with Alzheimer’s disease tend to have lower levels of lithium in their brains compared to healthy individuals. This observation led scientists to investigate whether restoring lithium levels could help protect the brain from the damage caused by the disease. To explore this possibility, researchers conducted laboratory experiments using mice genetically modified to develop Alzheimer’s disease. The study found that administering very low doses of lithium significantly improved the animals’ memory performance. In addition, the treatment reduced the harmful effects of brain cell damage that are typically associated with Alzheimer’s. These findings suggest that even small amounts of lithium may have protective effects on brain function. Scientists believe lithium works by helping to preserve the health of neurons, the specialized brain cells responsible for memory, learning, and thinking. The drug may also support communication between different regions of the brain by maintaining the connections between nerve cells. Since Alzheimer’s disease gradually destroys these connections, researchers believe lithium could potentially slow the progression of cognitive decline if administered during the early stages of the disease. Further support for this idea comes from a research paper published in the medical journal Translational Psychiatry. In the article, experts emphasized the need for more comprehensive studies to investigate the safety and effectiveness of low-dose lithium therapy for people with early-stage Alzheimer’s disease. They argued that while the initial findings are promising, larger clinical trials involving human participants are essential before any firm conclusions can be drawn. Experts from Alzheimer’s advocacy organizations have also responded cautiously to the research. Dr. Richard Oakley, Director of Research at the Alzheimer’s Society, said the findings contribute to the ongoing scientific discussion about lithium’s potential role in Alzheimer’s treatment. However, he warned that there is currently no conclusive evidence showing that lithium can prevent dementia or serve as a cure for Alzheimer’s disease. Dr. Oakley further explained that the human clinical trials conducted so far have been limited in size and scope. As a result, the available evidence is not yet strong enough to support the routine use of lithium for Alzheimer’s patients. He emphasized that larger, well-designed clinical studies are needed to determine the drug’s long-term benefits, possible side effects, and the most effective dosage. Alzheimer’s disease remains one of the world’s leading causes of dementia, affecting millions of people and placing a significant emotional and financial burden on families and healthcare systems. While current treatments can only help manage symptoms, researchers continue to search for therapies that can slow or stop the disease. If future studies confirm the benefits of low-dose lithium, this affordable and widely available medication could become an important addition to Alzheimer’s treatment. Until then, experts advise patients and caregivers not to use lithium for Alzheimer’s without medical supervision, as scientific evidence is still developing.